FINANCING AND ADDITIONAL SERVICESFinancing and Additional Services Agreement • October 12th, 2021 • RespireRx Pharmaceuticals Inc. • Pharmaceutical preparations
This Agreement supersedes all prior or contemporaneous negotiations, commitments, agreements and writings with respect to the subject matter hereof, all such other negotiations, commitments, agreements and writings will have no further force or effect, and the parties to any such other negotiation, commitment, agreement or writing will have no further rights or obligations thereunder. This is a Confidential Agreement and may only be viewed by the intended recipients and their legal and accounting representatives. RespireRx Pharmaceuticals Inc., which includes its subsidiaries and affiliates (the “Company”) is strictly prohibited from reproducing or disseminating this Agreement without the prior written consent of Primary Capital LLC (“PC”). Notwithstanding the foregoing, upon execution, PC consents that this agreement will be summarized and included as an exhibit in an offering statement or any other required or advisable filing with the SEC.
FINANCING AND ADDITIONAL SERVICES AMENDMENTFinancing and Additional Services Agreement • October 12th, 2021 • RespireRx Pharmaceuticals Inc. • Pharmaceutical preparations
FINANCING AND ADDITIONAL SERVICES AMENDMENTFinancing and Additional Services Agreement • October 12th, 2021 • RespireRx Pharmaceuticals Inc. • Pharmaceutical preparations • New York
Reference is made to the Financing and Additional Services Agreement between Primary Capital, LLC (“PC”) and RespireRx Pharmaceuticals, Inc. (the “Company”) dated August 6, 2021 (the “Agreement”). The undersigned parties hereby agree that the Agreement by and between PC and the Company shall be amended as follows:
